Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial.

By Paul M Ridker, Jean G Macfadyen, T. Thuren, Brendan M. Everett, Peter Libby, Robert J. Glynn. The Lancet, 2017

983 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Targeting Tumor Microenvironment for Cancer Therapy (2019, background): “Similarly, Canakinumab, an anti-IL-1β monoclonal antibody commonly used for treatment of inflammatory diseases, showed reduced incidence of lung cancer in a clinical trial (NCT01327846) of the role of IL-1β inhibition in patients with atherosclerosis that had myocardial infarction and with high leve”
Caspases in Cell Death, Inflammation, and Gasdermin-Induced Pyroptosis (2020, background): “gov number NCT01327846), focused on the application of canakinumab in a large cohort of over 10,000 patients with atherosclerosis and showed that IL-1β neutralization not only provided atherosclerotic benefits but also significantly protected these patients from lung cancer development (152, 203, 20”
NLRP3 Inflammasome and the IL-1 Pathway in Atherosclerosis. (2018, background): “Interestingly, canakinumab treatment significantly reduced incident lung cancer and lung cancer mortality in the CANTOS trial population.(215) This unexpected finding suggests that an anti-inflammatory therapy targeting IL-1β with canakinumab could also be beneficial for patients with certain cancer”